RxDoctor Payments Data

Hongsheng Wei, MD

Internal Medicine · Arcadia, CANPI 1689694580

Payments from drug & device makers

$11,276in general payments, 2019–2025

Across 634 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Johnson & Johnson$946
  • Amgen$651
  • Boehringer Ingelheim$642
  • Merck$556
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$11,14899%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,276 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$217,103
Medicare patients
407
Services billed
2,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin207$183,403
FarxigaDapagliflozin Propanediol196$155,274
CreonLipase/Protease/Amylase182$154,321
VascepaIcosapent Ethyl318$149,583
JanuviaSitagliptin Phosphate181$148,278
EliquisApixaban146$115,034
XareltoRivaroxaban120$95,888
RybelsusSemaglutide69$61,796
LinzessLinaclotide86$59,412
OrenciaAbatacept11$57,182
Icosapent Ethyl191$52,203
OzempicSemaglutide31$36,554
RestasisCyclosporine58$36,096
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$34,986
Cyclosporine67$33,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$2,218$249,828326 claims
Boehringer IngelheimJardiance, Tradjenta$642$209,471249 claims
MerckJanuvia, Janumet, Belsomra$556$178,823224 claims
AstraZenecaFarxiga$1,798$155,274196 claims
PfizerEliquis, Lyrica$412$128,480159 claims
Novo NordiskRybelsus, Ozempic$333$98,350100 claims
Johnson & JohnsonXarelto$946$95,888120 claims
GSKTrelegy Ellipta, Breo Ellipta$390$43,69164 claims
AmgenProlia$651$28,79818 claims
Lilly USA, LLCTrulicity$86$15,96615 claims
GileadVemlidy$273$15,84912 claims
Esperion Therapeutics, Inc.Nexlizet$364$11,55719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →